STOCK TITAN
  1. Home
  2. News
  3. ZVRA

Zevra Therapeutics, Inc. - ZVRA STOCK NEWS

Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.

Zevra Therapeutics, Inc. (symbol: ZVRA) is a pioneering rare disease company dedicated to developing transformational therapies for conditions with limited or no treatment options. By combining science, data, and patient needs, Zevra aims to deliver life-changing solutions to individuals living with rare diseases. Their mission is to address these unmet medical needs through unique, data-driven development and commercialization strategies.

Zevra Therapeutics utilizes its proprietary Ligand Activated Therapy (LAT) approach to create improved prodrug versions of FDA-approved medications. These prodrugs target high-need areas such as pain management, ADHD, and other central nervous system diseases. Through this innovative technology, Zevra is overcoming complex drug development challenges and making new therapies accessible to the rare disease community.

Recent achievements include significant advancements in their pipeline projects, particularly in pain and ADHD treatment. The company is also known for its strategic partnerships, which enhance its research and development capabilities and accelerate the commercialization of its therapies. Financially, Zevra has a solid foundation, allowing it to focus on its core mission of addressing rare diseases and improving patients' lives.

For up-to-date information, news, and latest developments, Zevra encourages stakeholders to stay connected through their official contact points:

News

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) resubmits NDA for arimoclomol, an investigational therapeutic candidate for Niemann-Pick disease type C (NPC) to the FDA. The NDA is expected to be classified as a Class II submission, subject to a review period within six months. The resubmission includes additional evidence, new data, and results from multiple non-clinical studies and early access programs, suggesting arimoclomol's potential to reduce the progression of NPC. Arimoclomol has been evaluated in 21 studies across Phase 1, 2, and 3 trials, showing promise in treating NPC and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
none
-
News

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) completes acquisition of Acer Therapeutics Inc., propelling the company into the commercial stage with OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs). The settlement of Acer’s warrant obligations diversifies Zevra's revenue and adds a quality healthcare investor to its shareholder base. The acquisition includes 2.96 million shares of Zevra stock and contingent value rights (CVRs) worth up to $76 million. Zevra also purchased Acer’s senior secured debt for $28.5 million, further strengthening its position in developing and commercializing treatments for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
acquisition
-
News

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

Rhea-AI Summary
Zevra Therapeutics, Inc. reported net revenue of $2.9M for Q3 2023 and ended the quarter with $83.4M in cash. The company is on track to resubmit the arimoclomol NDA by the end of the year. The proposed acquisition of Acer Therapeutics is expected to close in Q4 2023, diversifying Zevra's revenue with FDA-approved OLPRUVA® for urea cycle disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
earnings
News

Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET

Rhea-AI Summary
Zevra Therapeutics, Inc. will host a conference call and live audio webcast on November 7, 2023, to review its corporate and financial results for Q3 2023. The webcast will be accessible via the Investor Relations section of the company's website. The conference call dial-in information is provided. An archive of the webcast will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
conferences earnings
-
News

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

Rhea-AI Summary
Zevra Therapeutics supports the Niemann-Pick community on Global Niemann-Pick Disease Awareness Day and throughout Niemann-Pick Disease Awareness Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

Rhea-AI Summary
Zevra Therapeutics announces Neil F. McFarlane as new CEO, Christal M.M. Mickle transitions back to Chief Development Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
management
News

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

Rhea-AI Summary
Zevra Therapeutics to present data on arimoclomol program for Niemann-Pick Disease type C at 52nd CNS Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Rhea-AI Summary
Zevra Therapeutics (ZVRA) announces positive interim data from Phase 2 trial of KP1077 for idiopathic hypersomnia, indicating well-tolerated doses and potential benefits compared to current treatments. Topline data expected in H1 2024. Anticipated Phase 3 trial to be initiated by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
clinical trial
-
News

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

Rhea-AI Summary
Zevra Therapeutics to participate in Cantor Global Healthcare Conference on September 27, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
conferences
News

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

Rhea-AI Summary
Zevra Therapeutics presents study data on cardiovascular safety of serdexmethylphenidate (SDX) for idiopathic hypersomnia treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
none

FAQ

What is the current stock price of Zevra Therapeutics (ZVRA)?

The current stock price of Zevra Therapeutics (ZVRA) is $8.49 as of December 20, 2024.

What is the market cap of Zevra Therapeutics (ZVRA)?

The market cap of Zevra Therapeutics (ZVRA) is approximately 458.1M.

What does Zevra Therapeutics, Inc. specialize in?

Zevra Therapeutics focuses on developing transformational therapies for rare diseases using their proprietary LAT technology.

What is the company's mission?

The mission of Zevra Therapeutics is to bring life-changing therapeutics to people living with rare diseases.

What is the Ligand Activated Therapy (LAT) approach?

The LAT approach is a proprietary method used by Zevra to create improved prodrug versions of FDA-approved medications.

Which areas of medical needs does Zevra's technology target?

Zevra's technology targets high-need areas such as pain management, ADHD, and other central nervous system diseases.

Who are the primary contacts for investor relations?

Primary contacts include Nichol Ochsner, David Schull, and Ignacio Guerrero-Ros, Ph.D.

How does Zevra ensure the financial stability of their projects?

Zevra has a solid financial foundation, allowing them to focus on their core mission of addressing rare diseases.

What recent achievements has Zevra made?

Zevra has made significant advancements in their pipeline projects, especially in pain and ADHD treatment.

What kind of partnerships does Zevra engage in?

Zevra engages in strategic partnerships to enhance research, development, and accelerate commercialization efforts.

How can stakeholders stay updated with Zevra's latest news?

Stakeholders can stay updated by connecting with official contact points including Nichol Ochsner and representatives from Russo Partners.

What is the significance of Zevra’s prodrug development?

Zevra's prodrug development is significant as it creates improved versions of existing FDA-approved drugs to better meet patient needs.

Stock ZVRA logo
Zevra Therapeutics, Inc.

Nasdaq:ZVRA

ZVRA Rankings

#3167 Ranked by Market Cap
N/A Ranked by Dividends

ZVRA Stock Data

458.05M
49.84M
6.62%
54.46%
7.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CELEBRATION